Cocrystal compound of dihydromyricetin and preparation method thereof
By forming drug cocrystals with isonicotinamide or 4,4′-bipyridine, the problem of low water solubility of dihydromyricetin was solved, significantly improving its solubility and bioavailability.
Patent Information
- Application Number
- CN202210214481.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-03
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-03-03
AI Technical Summary
Dihydromyricetin has low solubility and poor permeability in water, resulting in low oral bioavailability.
By forming drug cocrystals with isonicotinamide or 4,4′-bipyridine, dihydromyricetin-isonicotinamide or dihydromyricetin-4,4′-bipyridine cocrystals are generated in the unit cell using non-covalent bonds at a specific molar ratio, thereby improving their crystallization properties and physicochemical properties.
It significantly improved the solubility and dissolution rate of dihydromyricetin, increasing the solubility in aqueous solution by 46%, the dissolution rate in hydrochloric acid solution at pH 1.2 by 1.3 times, and the bioavailability by nearly 2 times.
Smart Images

Figure CN114634474B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug co-crystals, and particularly relates to a co-crystal compound of dihydromyricetin and a preparation method thereof. Background Art
[0002] Dihydromyricetin is the main active ingredient from the traditional Chinese medicine rattan tea. It belongs to the flavonol class and has a variety of pharmacological activities such as scavenging free radicals, anti-oxidation, anti-thrombosis, anti-tumor, anti-inflammatory and other effects. A large number of existing studies have shown that dihydromyricetin has a significant therapeutic effect on liver diseases, preventing alcoholic liver disease, fatty liver disease, inhibiting liver cell deterioration, and reducing the incidence of liver cancer. Therefore, it has a clear and broad application prospect. However, dihydromyricetin has low solubility and poor permeability in water, resulting in low oral bioavailability. Therefore, improving the solubility and other properties of dihydromyricetin and thus improving bioavailability has become a problem to be solved. Summary of the invention
[0003] The object of the present invention is to provide a new cocrystal compound of dihydromyricetin (drug cocrystal), which can increase its solubility, improve stability and improve bioavailability compared with dihydromyricetin. The application of drug cocrystals in modifying the physicochemical properties of active pharmaceutical ingredients has attracted much attention. Drug cocrystals are new crystal forms formed by non-covalent interactions between active pharmaceutical ingredients (API) and cocrystal formers (CCF). The introduction of cocrystal formers can improve the crystallization performance and physicochemical properties of the drug itself.
[0004] The present invention uses isonicotinamide or 4,4'-bipyridine as a cocrystal forming compound, which is described in detail as follows:
[0005] Technical solution 1:
[0006] Dihydromyricetin-isonicotinamide drug cocrystal, with dihydromyricetin as the active pharmaceutical ingredient and isonicotinamide as the cocrystal former, is formed by the interaction and bonding of dihydromyricetin and isonicotinamide in a unit cell in a 1:1 manner through non-covalent bonds. Dihydromyricetin-isonicotinamide drug cocrystal belongs to the monoclinic system. Space group, axis length Axis angle α=100.827(4)°, β=106.501(4)°, γ=103.454(4)°, The chemical structures of the two components are shown below:
[0007]
[0008] The X-ray diffraction spectrum of the eutectic powder has characteristic peaks at 2θ of 5.54°, 6.56°, 10.16°, 12.16°, 12.44°, 13.40°, 14.14°, 15.20°, 16.72°, 18.25°, 18.74°, 20.60°, 21.60°, 23.12°, 24.03°, 24.68°, 25.30°, 27.34°, etc.
[0009] Differential scanning calorimetry (DSC) analysis showed that the cocrystal had an endothermic peak at 201°C and a melting point between dihydromyricetin and isonicotinamide.
[0010] The infrared spectrum of the eutectic is at 3379 cm -1 、1634cm -1 、842cm -1 、755cm -1 、630cm -1 There are characteristic peaks at other places.
[0011] Technical solution 2:
[0012] Dihydromyricetin-4,4'-bipyridine drug cocrystal, with dihydromyricetin as the active pharmaceutical ingredient and 4,4'-bipyridine as the cocrystal former, is formed by combining dihydromyricetin and 4,4'-bipyridine at a ratio of 1:2.5 through non-covalent bond interaction. Dihydromyricetin-4,4'-bipyridine drug cocrystal belongs to the triclinic system, with a space group of The axis length is Axis angle α=112.648(3)°, β=95.628(2)°, γ=95.179(2)°, The chemical structures of the two components are shown below:
[0013]
[0014] The X-ray diffraction spectrum of the eutectic powder has characteristic peaks at 2θ of 5.54°, 6.56°, 10.16°, 12.16°, 12.44°, 13.40°, 14.14°, 15.20°, 16.72°, 18.25°, 18.74°, 20.60°, 21.60°, 23.12°, 24.03°, 24.68°, 25.30°, 27.34°, etc.
[0015] DSC analysis showed that the cocrystal had an endothermic peak at 231°C and a melting point between dihydromyricetin and 4,4′-bipyridine.
[0016] The infrared spectrum of the eutectic is at 3395 cm -1 、1642cm -1、1457cm -1 、805cm -1 、732cm -1 、620cm -1 There are characteristic peaks at other places.
[0017] Preparation method:
[0018] 1. There are two methods for preparing dihydromyricetin-isonicotinamide cocrystals, which are described in detail as follows:
[0019] 1. A method for preparing a dihydromyricetin-isonicotinamide cocrystal, comprising the following steps: (1) dihydromyricetin-isonicotinamide is placed in a 5 mL grinding jar at a molar ratio of 1:1, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding. (2) The ground powder is placed in a glass container and added to a mixed solvent of methanol and other organic solvents, stirred until the powder is completely dissolved, and the solvent is slowly volatilized at room temperature to obtain prismatic crystals.
[0020] The organic solvent is acetonitrile, isopropanol, acetone, methanol or ethanol.
[0021] The organic solvent is a mixture of two or more of acetonitrile, isopropanol, acetone, methanol, ethanol or water.
[0022] 2. A method for preparing a dihydromyricetin-isonicotinamide cocrystal, comprising the following steps: (1) placing dihydromyricetin and isonicotinamide in a beaker at a certain molar ratio, adding a suitable solvent, and stirring at a constant temperature of 20 to 60° C. for 3 to 6 hours. (2) filtering and volatilizing the solution at room temperature to obtain a dihydromyricetin-isonicotinamide cocrystal powder.
[0023] The molar ratio of dihydromyricetin to isonicotinamide is 1:1 to 1:3.
[0024] The organic solvent is selected from acetonitrile, isopropanol, acetone, methanol and ethanol.
[0025] 2. There are two methods for preparing dihydromyricetin-4,4′-bipyridine cocrystals, which are described in detail as follows:
[0026] 1. A method for preparing a dihydromyricetin-4,4′-bipyridine cocrystal, comprising the following steps: (1) dihydromyricetin-4,4′-bipyridine is placed in a 5 mL grinding jar at a molar ratio of 1:2.5, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding. (2) the ground powder is placed in a glass container and added to a mixed solvent of acetonitrile and other organic solvents, stirred until the powder is completely dissolved, and the solvent is slowly volatilized at room temperature to obtain yellow needle-shaped crystals.
[0027] The organic solvent is acetonitrile, isopropanol, acetone, methanol or ethanol.
[0028] The organic solvent is a mixture of two or more of acetonitrile, isopropanol, acetone, methanol or ethanol or water.
[0029] 2. A method for preparing a dihydromyricetin-4,4′-bipyridine cocrystal, comprising the following steps: (1) placing dihydromyricetin and 4,4′-bipyridine in a beaker at a certain molar ratio, adding a suitable solvent, and stirring at a constant temperature of 20 to 60° C. for 12 to 24 hours. (2) filtering, and vacuum drying the filtered powder to obtain a dihydromyricetin-4,4′-bipyridine cocrystal powder.
[0030] The molar ratio of dihydromyricetin to 4,4'-bipyridine is 1:1-1:3.
[0031] The organic solvent is selected from acetonitrile, isopropanol, acetone, methanol or ethanol.
[0032] Beneficial Effects
[0033] The dihydromyricetin cocrystal provided by the present invention has significantly improved solubility and dissolution rate compared with the raw material drug dihydromyricetin, and the bioavailability of the cocrystal is significantly improved compared with the raw material drug dihydromyricetin, which saves the dosage of dihydromyricetin in the preparation of medicine, thereby achieving the purpose of improving its absorption, which is of great significance for improving the efficacy and safety of the drug. The solubility of the dihydromyricetin cocrystal provided by the present invention in aqueous solution is 46% higher than that of the raw material drug, and the dissolution rate in the hydrochloric acid solution with a pH of 1.2 is increased by about 1.3 times; its relative bioavailability is nearly 2 times higher than that of the raw material drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is the single crystal structure diagram of dihydromyricetin-isonicotinamide cocrystal;
[0035] Figure 2 is the powder X-ray diffraction (PXRD) pattern of dihydromyricetin-isonicotinamide cocrystal;
[0036] Figure 3 is a differential scanning calorimetry (DSC) diagram of dihydromyricetin-isonicotinamide cocrystal;
[0037] Figure 4 This is the infrared (IR) spectrum of dihydromyricetin-isonicotinamide cocrystal;
[0038] Figure 5 It is the dissolution curve of dihydromyricetin-isonicotinamide cocrystal;
[0039] Figure 6 It is the blood concentration curve of dihydromyricetin-isonicotinamide cocrystal;
[0040] Figure 7This is a single crystal structure diagram of dihydromyricetin-4,4′-bipyridine cocrystal;
[0041] Figure 8 is the powder X-ray diffraction (PXRD) pattern of dihydromyricetin-4,4′-bipyridine cocrystal;
[0042] Fig. 9 is a differential scanning calorimetry (DSC) diagram of dihydromyricetin-4,4′-bipyridine cocrystal;
[0043] Fig.10 is the infrared (IR) spectrum of dihydromyricetin-4,4′-bipyridine cocrystal;
[0044] Fig.11 is the dissolution curve of dihydromyricetin-4,4′-bipyridine cocrystal;
[0045] Fig.12 This is a blood concentration curve of dihydromyricetin-4,4′-bipyridine cocrystal. DETAILED DESCRIPTION
[0046] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the accompanying drawings of the present invention.
[0047] Embodiment 1:
[0048] Dihydromyricetin-isonicotinamide drug cocrystal, with dihydromyricetin as the active pharmaceutical ingredient and isonicotinamide as the cocrystal former, is formed by the interaction and bonding of dihydromyricetin and isonicotinamide in a unit cell in a 1:1 manner through non-covalent bonds. Dihydromyricetin-isonicotinamide drug cocrystal belongs to the monoclinic system. Space group, axis length Axis angle α=100.827(4)°, β=106.501(4)°, γ=103.454(4)°, The preparation method is as follows:
[0049] 1. A method for preparing a dihydromyricetin-isonicotinamide cocrystal, comprising the following steps: (1) dihydromyricetin-isonicotinamide is placed in a 5 mL grinding jar at a molar ratio of 1:1, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding. (2) The ground powder is placed in a glass container and added to a mixed solvent of methanol and other organic solvents, stirred until the powder is completely dissolved, and the solvent is slowly volatilized at room temperature to obtain prismatic crystals.
[0050] The organic solvent is acetonitrile, isopropanol, acetone, methanol or ethanol.
[0051] The organic solvent is a mixture of two or more of acetonitrile, isopropanol, acetone, methanol, ethanol or water.
[0052] 2. A method for preparing a dihydromyricetin-isonicotinamide cocrystal, comprising the following steps: (1) placing dihydromyricetin and isonicotinamide in a beaker at a certain molar ratio, adding a suitable solvent, and stirring at a constant temperature of 20 to 60° C. for 3 to 6 hours. (2) filtering and volatilizing the solution at room temperature to obtain a dihydromyricetin-isonicotinamide cocrystal powder.
[0053] The molar ratio of dihydromyricetin to isonicotinamide is 1:1 to 1:3.
[0054] The organic solvent is selected from acetonitrile, isopropanol, acetone, methanol and ethanol.
[0055] Embodiment 2:
[0056] Dihydromyricetin-4,4'-bipyridine drug cocrystal, with dihydromyricetin as the active pharmaceutical ingredient and 4,4'-bipyridine as the cocrystal former, is formed by combining dihydromyricetin and 4,4'-bipyridine at a ratio of 1:2.5 through non-covalent bond interaction. Dihydromyricetin-4,4'-bipyridine drug cocrystal belongs to the triclinic system, with a space group of Axis length Axis angle α=112.648(3)°, β=95.628(2)°, γ=95.179(2)°, The preparation method is as follows:
[0057] 1. A method for preparing a dihydromyricetin-4,4′-bipyridine cocrystal, comprising the following steps: (1) dihydromyricetin-4,4′-bipyridine is placed in a 5 mL grinding jar at a molar ratio of 1:2.5, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding. (2) the ground powder is placed in a glass container and added to a mixed solvent of acetonitrile and other organic solvents, stirred until the powder is completely dissolved, and the solvent is slowly volatilized at room temperature to obtain yellow needle-shaped crystals.
[0058] The organic solvent is acetonitrile, isopropanol, acetone, methanol or ethanol.
[0059] The organic solvent is a mixture of two or more of acetonitrile, isopropanol, acetone, methanol or ethanol or water.
[0060] 2. A method for preparing a dihydromyricetin-4,4′-bipyridine cocrystal, comprising the following steps: (1) placing dihydromyricetin and 4,4′-bipyridine in a beaker at a certain molar ratio, adding a suitable solvent, and stirring at a constant temperature of 20 to 60° C. for 12 to 24 hours. (2) filtering, and vacuum drying the filtered powder to obtain a dihydromyricetin-4,4′-bipyridine cocrystal powder.
[0061] The molar ratio of dihydromyricetin to 4,4'-bipyridine is 1:1-1:3.
[0062] The organic solvent is selected from acetonitrile, isopropanol, acetone, methanol or ethanol.
[0063] The instruments for detecting the structure and performance of drug co-crystals in the present invention are as follows:
[0064] 1. The single crystal structure of the eutectic was determined by Rigaku Oxford X-ray single crystal diffractometer.
[0065] 2. X-ray powder diffractometer The X-ray powder diffractometer was used to measure the chromatographic data at a scanning rate of 5° / min and a 2θ range of 5°-45°.
[0066] 3. Differential Scanning Calorimetry Analysis The differential scanning calorimeter was used to measure the temperature in the range of room temperature to 450°C.
[0067] 4. Infrared spectra were measured by Nicolet Nexus 470 infrared spectrometer with a scanning range of 400-4000cm -1 .
[0068] 5. Solubility, dissolution rate and blood concentration were determined by Waters 2695 high performance liquid chromatograph.
Claims
1. A co-crystal compound of dihydromyricetin, wherein dihydromyricetin and a co-crystal former form a crystal through non-covalent interaction; The co-crystal former is 4,4′-bipyridine; dihydromyricetin and 4,4′-bipyridine are combined in a ratio of 1:2.5 through non-covalent bond interaction to form dihydromyricetin-4,4′-bipyridine co-crystal, and the space group is The axis length is Axis angle α=112.648(3)°, β=95.628(2)°, γ=95.179(2)°, The preparation method of dihydromyricetin-4,4′-bipyridine cocrystal is as follows: (1) dihydromyricetin-4,4′-bipyridine is placed in a 5 mL grinding jar at a molar ratio of 1:2.5, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding; (2) the ground powder is placed in a glass container and added into a mixed solvent of acetonitrile and other organic solvents, and stirred until the powder is completely dissolved, and the solvent is slowly evaporated at room temperature to obtain yellow needle-shaped crystals; the organic solvent is acetonitrile or isopropanol or acetone or methanol or ethanol or a mixture of two or more.
2. A co-crystal compound of dihydromyricetin, wherein dihydromyricetin and a co-crystal former form a crystal through non-covalent interaction; the co-crystal former is isonicotinamide, and dihydromyricetin and isonicotinamide interact and combine in a 1:1 manner in a unit cell through non-covalent bonds to form a dihydromyricetin-isonicotinamide co-crystal, Space group, axis length is Axis angle α=100.827(3)°, β=106.501(2)°, γ=103.454(2)°, The preparation method of dihydromyricetin-isonicotinamide cocrystal is as follows: (1) dihydromyricetin-isonicotinamide is placed in a 5 mL grinding jar at a molar ratio of 1:1, and 2 to 3 drops of acetonitrile as a grinding aid solvent are added for grinding; (2) the ground powder is placed in a glass container and a mixed solvent of methanol and other organic solvents is added, and after stirring until the powder is completely dissolved, the solvent is slowly evaporated at room temperature to obtain prismatic crystals; the organic solvent is acetonitrile or isopropanol or acetone or methanol or ethanol or a mixture of two or more.
Citation Information
Patent Citations
Myricetin pharmaceutical eutectic crystal and preparation method thereof
CN103819440A
Myricetin 4, 4'-dipyridyl ethanol eutectic crystal and preparation method thereof
CN106699718A
Dihydromyricetin-berberine hydrochloride pharmaceutical co-crystals and preparation method thereof
CN110054606A
Hesperetin and isonicotinamide eutectic, and preparation method, composition and application thereof
CN113214208A
